Objective. Evaluate the effects of continuous positive airway pressure (CPAP) on C-reactive protein (CRP) levels, reported either as a primary or secondary end point among patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) based on a meta-analysis of published studies.
S ystemic inflammation is ever increasingly being linked to a number of chronic diseases such as atherosclerosis, coronary artery and cerebrovascular disease, chronic obstructive pulmonary disease, and osteoporosis. In addition, numerous systematic studies have identified inflammatory mediators as both a cause and a risk factor for the morbidity and mortality associated with these conditions. 1 C-reactive protein (CRP) is an easily testable, sensitive biomarker for systemic inflammation. Multiple studies have shown that elevated CRP is associated with the risk of future cardiac events, and the American Heart Association (AHA) recommends using CRP in risk factor assessment in adults without known cardiac disease. In addition to cardiac disease, there is also evidence linking elevated CRP levels to obstructive sleep apnea-hypopnea syndrome (OSAHS).
Obstructive sleep apnea-hypopnea syndrome is characterized by nighttime episodes of apnea and/or hypopnea, which result in a temporary oxygen desaturation. This results in persistent hypertension and prolonged systemic inflammation, both of which are secondary to sympathetic activation. 2 It is also thought that more severe OSAHS can lead to daytime hypoxic episodes that cause heart and endorgan damage by this same mechanism. 2 Many studies have shown that there is a strong association between OSAHS and cardiovascular disease. 3, 4 In addition, recent studies have found CRP to be elevated in patients with OSAHS. 5 Furthermore, several studies have shown levels of CRP to correlate with severity of OSAHS. [6] [7] [8] [9] [10] [11] [12] [13] It remains controversial, however, if these results are applicable to all patients suffering from OSAHS.
A useful tool for the noninvasive treatment of OSAHS is continuous positive airway pressure (CPAP). Depending on the ability of the patient to tolerate it, CPAP can offer significant benefits. Continuous positive airway pressure eliminates hypoxic episodes and results in improved sleep. In addition, compliance with therapy can result in significant reduction in systolic/diastolic hypertension, particularly in drug-resistant patients. Furthermore, CPAP has also been shown to improve overall cardiac function and reduce mortality. 14 Given the prevalence of OSAHS and its adverse consequences on cardiovascular health, several studies have examined the effect of CPAP on CRP levels. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Unfortunately, these trials were small in sample size, and many lacked sufficient statistical power to detect a significant change in serum CRP following CPAP therapy.
The purpose of this investigation is to evaluate the effects of CPAP on CRP levels, reported either as a primary or secondary end point, among patients with OSAHS. We hypothesize that, in gaining significant numbers of patients, we will clarify the relationship between CPAP and CRP, as well as the relationship between CRP and OSAHS.
Materials and Methods

Literature Search
A computerized search was conducted to identify literature on the topic of CRP levels in patients with OSAHS after treatment with CPAP. The comprehensive literature search was performed using PubMed, Ovid, and the Cochrane database. Search terms included the following keywords: Creactive protein and CPAP; OSAHS, CRP and CPAP; CPAP and inflammatory markers; and CPAP and cardiovascular risk factors. The reference sections of identified studies were examined for additional relevant articles to review.
The initial search was performed independently by the reviewers Michael Friedman (M.F) .and Michelle Fisher (M.D.F). Based on the search results and reference section reviews, 136 articles were identified. Initial screening of article titles and abstracts retrieved from the search was performed based on the inclusion/exclusion criteria. After discussion between the 2 reviewers, 64 articles were found to be relevant to this study.
The 64 articles then underwent second-stage review. The articles were read and discussed in detail by the 2 reviewers. Those articles that did not meet inclusion criteria pertaining to automatic positive airway pressure (APAP)/CPAP compliance were excluded. In some articles, key data were missing, including pre-and posttreatment CRP levels. The authors of the articles were contacted to try to receive additional data. The articles were excluded if the authors did not respond with enough data for inclusion. At the end of this process, 10 studies were identified that presented adequate data and met inclusion criteria ( Figure 1 ).
Inclusion/Exclusion Criteria
The study was designed to review those studies reporting CRP levels before and after CPAP treatment in patients with OSAHS. The research inquiry for the study was to determine the effect of APAP or CPAP in patients with OSAHS on CRP levels. The following inclusion criteria were used:
1. All subjects reported must be older than 18 years. 2. The study must have both pre-and post-APAP/ CPAP CRP values reported. 3. Pretreatment polysomnography must be abnormal, resulting in the diagnosis of OSAHS. 4. All levels of OSAHS (mild, moderate, and severe) were included. 5. Subjects must have reported using CPAP for .4 h/ night, .5 times/wk. 6. APAP/CPAP had to be used for 1 month before repeat CRP.
Only studies written in English were included for review. In addition, case reports, abstracts, and letters to the editor were not reviewed.
Statistical Analysis
Data were retrieved and were reviewed systematically. All calculations and plot synthesis were carried out using the Comprehensive Meta-Analysis Software Package (Englewood, New Jersey).
Cochran's Q test for determining heterogeneity
was applied, where P \ .05 was considered a significant difference of sample population between studies. The I 2 value was calculated from pre-and post-CPAP CRP levels. 2. Standard difference in means between pre-and posttreatment CRP levels was calculated using the random effects model. All studies were weighted for effect. A forest plot was synthesized. 3. Sensitivity analysis was done to determine the effect of study design (randomized controlled trial, case controlled, case series), treatment modality (CPAP/APAP), body mass index (BMI \30), and duration of treatment (3 months). Forest plots were synthesized. 4. Analysis of publication bias was performed by calculating Egger's regression intercept.
Precision funnel plots with imputed values were created using Duval and Tweedie's trim and fill method.
Analysis of Bias
After extensive discussion between the reviewers, risk-ofbias tables were created for included articles.
Results
Ten studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] comprising data from a total of 325 patients were included for review ( Table 1) . Of those analyzed, 93.14% (80%-100%) were men, and the mean (weighted) age was 51.54 years (range, 44-55.3 years).
The average duration of treatment was 4 months (range, 1-6 months), and the average nightly use of CPAP was 5.49 hours (range, 4.7-6.6 hours). The average BMI was 33.12 (range, 29.3-46.1). The average apnea-hypopnea index was 55.7 (46-91) events per hour, and the average Epworth Sleepiness Scale (ESS) score was 14.7 (10.5-15.8). The level of evidence of each study is also included. Among the included studies, 2 are randomized controlled studies, 2 are case-controlled studies, and 6 are case series.
Quality of Data
Analysis of the types of bias associated with each type of study is outlined in Table 2a -c.
Effect of Positive Pressue on CRP Levels
The mean (SD) CRP of these studies reduced from 4.3 60.39 mg/dL to 3.5 60.46 mg/dL following CPAP treatment (P = .002) ( Table 3) . This corresponds to a total standard mean difference of -0.485 (-0.731, -0.240; P \ .000) ( Figure 2 ). I 2 , based on pre-and post-CRP levels, was 73.05. As such, if all studies are included, CPAP does lead to a significant reduction in CRP levels.
Sensitivity Analysis-Study Type
Randomized controlled trials. The total standard mean difference between the randomized controlled studies is not significant, with a corresponding value of -0.674 (-1.740, 0.391; P = .215) ( Figure 3 ). As such, among the 2 studies 15 Randomized and blinded study on 100 men with moderate/severe OSA. Patients received either therapeutic or sham CPAP. Blood levels of markers were taken at 4 weeks and reported. Given the short duration, there may be a reporting bias that may not accurately represent the true long-term effects. In addition, there is no indication that there was control for collection bias. Drager et al 18 Randomized study of 24 patients with severe OSA treated with either CPAP or no treatment for 4 months. At that time, CRP levels, catecholamine levels, and arterial measurements were taken/reviewed by people blinded to the treatment. Although collection bias was controlled for, there was no blinding in the treatment, which may act as a source of bias.
(b) Case-Controlled Studies
Carneiro et al 16 Plasma levels of inflammatory cytokines were evaluated in 16 obese males with OSA with 13 BMI-matched controls. Plasma levels were redrawn 3 months after CPAP therapy. a Yokoe et al 21 Thirty patients with OSA were matched with 14 obese control patients. Inflammatory markers were drawn prior to and after 1 month of CPAP treatment in the OSA group. a (c) Case-Series Studies Dorkova et al 17 Thirty-two patients with severe OSA and metabolic syndrome were treated with 8 weeks of CPAP therapy. CRP and inflammatory mediators were analyzed pre-and posttreatment. a Drummond et al 19 Ninety-eight male patients with moderate to severe OSA were treated with APAP. CRP levels were drawn prior to treatment and at 6 months. a Iesato et al 20 Study of 36 male patients with OSA, selected from a larger group to undergo 3-month CPAP therapy. CRP levels and inflammatory markers were drawn before and after treatment. a Ishida et al 22 Fifty-five patients with OSA were treated with CPAP for 6 months. Pre-and post-CRP levels were drawn, and overall compliance was noted. CRP levels were compared in compliant and noncompliant patients. a Partuno et al 23 Thirty-one patients with severe OSA underwent standard CPAP titration and then were randomized to either CPAP or APAP for 3 months. CRP levels were drawn prior to and after treatment. a Steiropoulos et al 24 Fifty-three patients newly diagnosed with OSA were treated with CPAP for 6 months.
Pre-and post-CRP levels were drawn. CRP levels were compared in compliant and noncompliant patients. a
Abbreviations: APAP, automatic positive airway pressure; BMI, body mass index; CPAP, continuous positive airway pressure; CRP, C-reactive protein; OSA, obstructive sleep apnea. a Given the lack of randomization/blinding, there is a risk of sampling/selection, measurement, reader, and reporting bias.
with the ''highest level of evidence,'' CPAP does not lead to a significant reduction in CRP.
Case-controlled/case-series trials. The total standard mean difference between the case-controlled studies is significant, with a corresponding value of -1.068 (-1.641, -0.495; P = .000) ( Figure 4) . The total standard mean difference between the case-series studies is significant, with a corresponding value of -0.354 (-0.606, -0.101; P = .006) ( Figure 5 ). As such, among the studies with ''lower-level evidence,'' CPAP does lead to a significant reduction in CRP levels.
Sensitivity Analysis-Intervention Type CPAP/APAP. The total standard mean difference between the CPAP studies is significant, with a corresponding value of -0.720 (-1.072, -0.369; P = 0.000) ( Figure 6 ). The total standard mean difference between the APAP studies is not significant, with a corresponding value of -0.251 (-0.517, 0.015; P = .065) ( Figure 7) . As such, although CPAP treatment does significantly lower CRP levels, treatment with APAP does not.
Sensitivity Analysis-Population Type
BMI \30. The total standard mean difference between the studies with an average BMI \30 is significant, with a corresponding value of -0.455 (-0.678, -0.232; P = .000) ( Figure 8 ). As such, the analysis reveals that CPAP treatment leads to a significant reduction in CRP in patients with a BMI \30. Duration of treatment. The total standard mean difference between the studies with a CPAP duration of 3 months is significant, with a corresponding value of -0.559 (-0.826, -0.291; P = .000) ( Figure 9 ). As such, the analysis reveals that CPAP treatment leads to a significant reduction in CRP in patients treated for 3 months.
Assessment of Bias
Publication bias was assessed both mathematically using Egger's regression intercept (P = .000) and graphically using a precision funnel plot with Duval and Tweedie's trim and fill ( Figure 10) . Five possible unpublished studies were ''found'' (black dots), shifting the standard mean difference to -0.232 (-0.473, 0.009). This suggests that publication bias is likely and that if these studies were ''added,'' they would likely negate our original results on the effectiveness of CPAP at lowering CRP levels.
Discussion
The limitations of meta-analysis, especially pertaining to observational studies, include selection bias and confounding factors. Although the primary reviewers attempted to lessen the potential of patient selection bias through the use of the inclusion/exclusion criteria as outlined, this itself may represent a source of selection bias. One example of this was the exclusion of 17 articles that were not written in English. Although unavoidable, given the language limitations of the 2 reviewers, the exclusion of these articles may potentially weigh results in favor of one outcome over another. The consequence of limiting selection bias is the inclusion of many possible confounding factors. Assessment of publication bias using Egger's regression was significant, suggesting that there is likely publication bias. This is further illustrated in the precision funnel plot by the lack of smaller, less precise studies to the right of the mean. When these studies are imputed to the analysis, the reduction in CRP is no longer significant. In addition, the meta-analysis included multiple case-controlled studies and case-series studies, each with the possibility of a high degree of experimental bias. As such, our results, although significant, are overshadowed by the inherent limitations and number of studies available for analysis.
As the included studies had varied protocols (with respect to inclusion/exclusion criteria, as well as diagnostic definition of OSAHS), the random effects model was used. This model assumes that the studies were drawn from populations that differ from each other in parameters that may have a direct effect on the outcomes and that any observed differences will be due to random error or true variation in effect. This method is considered the standard choice for outcomes related to medical decision making as conclusions may be extrapolated beyond the study. 25 Another limitation to our study is the controversy over the relationship between CRP and OSAHS.
The main controversy surrounding the relationship between CRP and OSAHS is whether a relationship actually exists at all. Numerous studies suggest that elevated CRP levels in OSAHS patients are secondary to obesity and not related to the OSAHS diagnosis, regardless of the severity of the disease. 26, 27 These studies have demonstrated that CRP levels strongly correlate with the amount of visceral and total body fat, as well as indicators of obesity such as waist circumference, waist-to-hip ratio, and BMI. In a study by Rexrode et al, 28 the authors concluded that women with a BMI in the upper quartile have an odds ratio of CRP elevation above the 75th percentile of 12.2. In addition, obesity itself is a risk factor for OSAHS. Therefore, any elevation of CRP noted in obese OSAHS patients may be a reflection of chronic inflammation due to obesity and not related to OSAHS-induced chronic hypoxia, as studies suggest that nonobese patients with OSAHS may not have statistically increased levels of systemic inflammatory markers.
Recent studies, however, suggest that CRP elevation may be independent from visceral obesity in patients with OSAHS. In a study by Punjabi and Beamer, 6 the authors suggest that, in the absence of hypertension, diabetes, and cardiovascular disease, CRP is related to the degree of OSAHS with and without taking into account age and various parameters of obesity. In addition, Liu et al 13 showed that in a population of 111 healthy males, CRP is associated with OSAHS severity independent of BMI. These results suggest that factors other than adiposity may be responsible for the proinflammatory state seen in OSAHS. In addition, they suggest that CRP levels can be evaluated both in and between studies, irrespective of the average BMI of the study population.
For the purposes of this study, we are assuming the latter hypothesis, that CRP is elevated in patients with OSAHS. Although we acknowledge that our study population is, by definition, obese (BMI .30), the average pretreatment CRP levels are higher than those expected in obese patients free from OSAHS. In addition, the posttreatment BMI is unchanged. As a tool for the noninvasive treatment of OSAHS, CPAP can offer significant benefits. Studies show that depression decreases and quality of life increases in patients who use CPAP. 14 In addition, compliance with therapy can result in significant reduction in systolic/diastolic hypertension, particularly in drug-resistant patients. Yet, although CPAP can improve OSAHS symptoms and sequelae, there is little agreement as to its effect on CRP levels. Assuming that OSAHS is an independent variable that is associated with elevated CRP levels, further controversy exists as to whether CPAP can reduce these levels.
Our initial literature search returned 136 articles. After exercising the exclusionary criteria, 10 studies remained for analysis, consisting of a total of 325 patients. The results of our meta-analysis suggest that CPAP is effective in reducing CRP in patients treated for OSAHS. Furthermore, because we analyzed our data using the random effects model, these results suggest that despite the variance among study protocol and patient population, our results may represent the true response of CRP levels to CPAP treatment.
A sensitivity analysis of the included studies suggests that all case studies, case-controlled series, CPAP studies, studies treating patients less than 3 months, and studies with participants with a mean BMI \30 yielded significant total standard mean differences. As discussed, these studies have a high risk of bias and a low level of evidence. As a result, the strength of our conclusion is somewhat limited by the quantity of quality studies available. Although BMI did not significantly change within each respective study, our results suggest that CRP levels in patients with a BMI \30 may respond better to CPAP therapy. In addition, patients treated with CPAP may have a greater reduction in CRP than those treated with APAP, and it may require as little as 3 months to observe these results.
When all studies are included, CPAP treatment appears to significantly lower CRP levels by 0.11 mg/dL, or 17.8%. The actual clinical significance of this witnessed decrease remains in question. Even if there is a significant reduction in CRP level, the mean posttreatment levels suggest that patients remain at high risk for cardiovascular morbidity (.3 mg/L as defined by the Centers for Disease Control and Prevention guidelines). 29 There is ample evidence that CPAP treatment decreases hypertension and improves insulin sensitivity as well as overall cardiac function. Therefore, patients may be getting benefit from CPAP that is not accurately reflected in CRP. This may suggest a mechanism of improvement that is independent from CRP production. These mechanisms may be peripheral such as improved quality of life/daytime wakefulness, leading to further daytime activity and improved cardiac output during exercise, or more central mechanisms such as reduced sympathetic activity during sleep and wakefulness.
Conclusion
Although the quantity of randomized controlled studies is lacking, treatment with CPAP appears to have a significant effect on decreasing CRP levels in patients treated for OSAHS, as determined by pre-and posttreatment serum levels. Unfortunately, there still exists debate as to the true relationship between CRP and OSAHS, as well as the clinical significance of any reduction. Closely following patients for improvement in sleep study indices and clinical symptomatology remains the mainstay of treatment. Further research is needed to determine those who will have the greatest reduction with CPAP treatment, as well as to understand the interplay between cardiac risk factor reduction and reduction of CRP as it relates to patients with OSAHS.
